Back to search results

COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study

Abroad (travel likely)RecruitingPHASE2

Conditions

Breast Cancer Invasive · Metastatic Cancer · Oligoprogressive

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Noordwest Ziekenhuisgroep, Alkmaar, Netherlands

    Contact: Study coordinator (S Vrijaldenhoven, MD)
    Contact: Principal Investigator (S Vrijaldenhoven, MD)

  • Antoni van Leeuwenhoek, Amsterdam, Netherlands

    Contact: Study coordinator (G Sonke, MD) · g.sonke@nki.nl
    Contact: Study coordinator (A Almekinders, MD) · c.almekinders@nki.nl
    Contact: Principal Investigator (G Sonke, MD)

  • Rijnstate, Arnhem, Netherlands

    Contact: Study coordinator (K J Beelen, MD) · info@rijnstate.nl · +31880058888
    Contact: Principal Investigator (K J Beelen, MD)

  • Deventer ziekenhuis, Deventer, Netherlands

    Contact: Study coordinator (A Imholz, MD)
    Contact: Principal Investigator (A Imholz, MD)

  • ADRZ, Goes, Netherlands

    Contact: Study coordinator (E van Vliet, MD) · researchbureau@adrz.nl · +31881250000
    Contact: Principal Investigator (E van Vliet, MD)

  • Martini ziekenhuis, Groningen, Netherlands

    Contact: Study coordinator (A van der Velden, MD)
    Contact: Principal Investigator (A van der Velden, MD)

  • Antonius ziekenhuis, Utrecht, Netherlands

    Contact: Study coordinator (M Agterof, MD)
    Contact: Principal Investigator (M Agterof, MD)
Study leads

  • G Sonke

    Principal Investigator

    The Netherlands Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)